- Home
- CYH vs PHAR Comparison
CYH vs PHAR Comparison
Compare CYH & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- PHAR
- Stock Information
- Founded
- CYH 1985
- PHAR 1988
- Country
- CYH United States
- PHAR Netherlands
- Employees
- CYH N/A
- PHAR N/A
- Industry
- CYH Hospital/Nursing Management
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- CYH Health Care
- PHAR Health Care
- Exchange
- CYH Nasdaq
- PHAR Nasdaq
- Market Cap
- CYH 623.8M
- PHAR 679.0M
- IPO Year
- CYH 1991
- PHAR N/A
- Fundamental
- Price
- CYH $3.42
- PHAR $9.10
- Analyst Decision
- CYH Hold
- PHAR Strong Buy
- Analyst Count
- CYH 6
- PHAR 3
- Target Price
- CYH $4.40
- PHAR $27.00
- AVG Volume (30 Days)
- CYH 1.7M
- PHAR 6.7K
- Earning Date
- CYH 02-18-2025
- PHAR 03-13-2025
- Dividend Yield
- CYH N/A
- PHAR N/A
- EPS Growth
- CYH N/A
- PHAR N/A
- EPS
- CYH N/A
- PHAR N/A
- Revenue
- CYH $12,551,000,000.00
- PHAR $285,745,000.00
- Revenue This Year
- CYH $1.16
- PHAR $20.08
- Revenue Next Year
- CYH $1.18
- PHAR $9.22
- P/E Ratio
- CYH N/A
- PHAR N/A
- Revenue Growth
- CYH 0.81
- PHAR 30.64
- 52 Week Low
- CYH $2.51
- PHAR $6.65
- 52 Week High
- CYH $6.29
- PHAR $13.20
- Technical
- Relative Strength Index (RSI)
- CYH 60.10
- PHAR 46.44
- Support Level
- CYH $2.88
- PHAR $9.37
- Resistance Level
- CYH $3.04
- PHAR $10.01
- Average True Range (ATR)
- CYH 0.14
- PHAR 0.55
- MACD
- CYH 0.08
- PHAR -0.14
- Stochastic Oscillator
- CYH 99.12
- PHAR 16.26
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About PHAR Pharming Group N.V.
Pharming Group is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. It is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines to serve the unserved rare disease patients. Its product includes Ruconest. The revenue is generated from the United States.